Lenvima

• 

Health-related quality of life for kidney cancer patients on pembrolizumab/lenvatinib

By Sharon Deveson Kell|2021-08-20T08:07:49+00:0020 Aug 2021|Drug treatments|

In this video, Dr Bradley McGregor from the Dana-Farber Cancer [...]

Read More

Comments Off on Health-related quality of life for kidney cancer patients on pembrolizumab/lenvatinib

• 

FDA approves pembrolizumab plus lenvatinib combination for advanced kidney cancer

By Sharon Deveson Kell|2021-08-20T07:58:02+00:0020 Aug 2021|Drug treatments|

The US Food and Drug Administration (FDA) has approved the [...]

Read More

Comments Off on FDA approves pembrolizumab plus lenvatinib combination for advanced kidney cancer

• 

Lenvatinib plus pembrolizumab in for untreated and previously treated metastatic kidney cancer

By Sharon Deveson Kell|2021-07-14T14:34:16+00:0012 Jul 2021|Drug treatments|

Results from a phase Ib/II study looking at lenvatinib plus [...]

Read More

Comments Off on Lenvatinib plus pembrolizumab in for untreated and previously treated metastatic kidney cancer

• 

ASCO 2021: Health-related quality of life for lenvatinib plus pembrolizumab for advanced kidney cancer

By Robert|2021-07-07T12:45:48+00:008 Jun 2021|Drug treatments|

Results from the phase 3 CLEAR study were presented at [...]

Read More

Comments Off on ASCO 2021: Health-related quality of life for lenvatinib plus pembrolizumab for advanced kidney cancer

• 

ASCO GU 2021: Combinations of lenvatinib plus pembrolizumab or everolimus improved survival in untreated patients with advanced kidney cancer

By Sharon Kell|2021-02-15T11:14:12+00:0015 Feb 2021|Drug treatments|

Results from the phase 3 CLEAR study, presented at the [...]

Read More

Comments Off on ASCO GU 2021: Combinations of lenvatinib plus pembrolizumab or everolimus improved survival in untreated patients with advanced kidney cancer

• 

Pembrolizumab plus lenvatinib for first-line treatment of kidney cancer shows promise

By Sharon Kell|2020-12-10T09:10:10+00:0010 Dec 2020|Uncategorized|

Results from the phase 3 KEYNOTE-581/CLEAR trial show that the [...]

Read More

Comments Off on Pembrolizumab plus lenvatinib for first-line treatment of kidney cancer shows promise

• 

Lenvatinib plus everolimus for non clear cell kidney cancer

By Sharon Kell|2020-11-20T15:54:19+00:0020 Nov 2020|Uncategorized|

Treating non-clear cell renal cell carcinoma (RCC) is challenging because [...]

Read More

Comments Off on Lenvatinib plus everolimus for non clear cell kidney cancer

• 

Lenvatinib plus pembrolizumab shows promise in solid tumours

By Sharon Kell|2020-01-31T17:27:07+00:0031 Jan 2020|Drug treatments|

The combination of lenvatinib plus pembrolizumab has shown promise in [...]

Read More

Comments Off on Lenvatinib plus pembrolizumab shows promise in solid tumours

• 

SMC approves lenvatinib plus everolimus combination for second-line treatment of advanced kidney cancer

By Sharon Kell|2019-11-12T09:10:10+00:0012 Nov 2019|Drug treatments|

We are delighted to announce that the Scottish Medicines Consortium (SMC), [...]

Read More

Comments Off on SMC approves lenvatinib plus everolimus combination for second-line treatment of advanced kidney cancer

• 

Lenvatinib plus pembrolizumab combination shows promise in metastatic kidney cancer

By Sharon Kell|2019-11-06T17:46:10+00:006 Nov 2019|Drug treatments|

Interim results from an ongoing clinical trial of lenvatinib and [...]

Read More

Comments Off on Lenvatinib plus pembrolizumab combination shows promise in metastatic kidney cancer